Perspective Therapeutics (NYSEAMERICAN:CATX) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Perspective Therapeutics (NYSEAMERICAN:CATX) announced its quarterly earnings results on Monday. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03), FiscalAI reports. Perspective Therapeutics had a negative return on equity of 41.92% and a negative net margin of 28,467.97%. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.06 million.

Perspective Therapeutics Price Performance

Shares of NYSEAMERICAN CATX traded up $0.02 during mid-day trading on Monday, hitting $0.86. The company had a trading volume of 2,930,748 shares, compared to its average volume of 2,354,898. The firm has a 50-day simple moving average of $2.34 and a two-hundred day simple moving average of $3.49. Perspective Therapeutics has a one year low of $0.78 and a one year high of $6.16.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on CATX. BTIG Research reissued a “buy” rating on shares of Perspective Therapeutics in a research note on Monday, October 26th. Piper Sandler decreased their price target on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Perspective Therapeutics in a research note on Friday, October 30th. William Blair started coverage on shares of Perspective Therapeutics in a report on Friday, September 18th. They issued an “outperform” rating on the stock. Finally, Bank of America cut their price objective on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating on the stock in a research report on Friday, August 14th. Nine research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $10.50.

About Perspective Therapeutics

Perspective Therapeutics, Inc is a biotechnology company developing precision-targeted radiopharmaceutical treatments for cancer. The company’s platform is designed to deliver alpha-particle radiation directly to tumor cells by pairing radioactive isotopes with molecules that bind to specific cancer targets, with the goal of limiting damage to surrounding healthy tissue.

The company’s lead programs include VMT-?-NET, an investigational therapy directed at somatostatin receptor 2, a target commonly expressed by neuroendocrine tumors.